---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062943"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:02:47.067489+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annexon Q3 net loss $32.5M, cash $165.3M; Phase 3 GBS enrollment complete, data H1 2024

## Summary
- Net loss of $32.5M ($0.43 per share) vs $35.1M ($1.42 per share) in Q3 2022.
- Cash, equivalents and investments of $165.3M as of Sep 30, 2023; runway into Q2 2025.
- R&D expenses flat at $27.9M; G&A down to $6.9M from $8.2M.
- Phase 3 GBS trial enrolled 225 patients; topline pivotal data expected first half 2024.
- ANX007 for GA granted EMA PRIME designation; global Phase 3 regulatory discussions ongoing.

## SEC filing metadata
- accession: 0000950170-23-062943
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017023062943/0000950170-23-062943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017023062943/annx-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062943
- JSON: https://secwatch.observer/filing/0000950170-23-062943.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.